1. Home
  2. TCRT vs GOVX Comparison

TCRT vs GOVX Comparison

Compare TCRT & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alaunos Therapeutics Inc.

TCRT

Alaunos Therapeutics Inc.

HOLD

Current Price

$2.72

Market Cap

7.2M

Sector

Health Care

ML Signal

HOLD

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

HOLD

Current Price

$2.84

Market Cap

8.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCRT
GOVX
Founded
1998
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2M
8.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TCRT
GOVX
Price
$2.72
$2.84
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$175.00
AVG Volume (30 Days)
51.9K
229.4K
Earning Date
11-14-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,000.00
$3,353,560.00
Revenue This Year
$5,680,500.00
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.52
52 Week Low
$1.31
$2.86
52 Week High
$6.20
$57.88

Technical Indicators

Market Signals
Indicator
TCRT
GOVX
Relative Strength Index (RSI) N/A 78.25
Support Level N/A $0.16
Resistance Level N/A $4.40
Average True Range (ATR) 0.00 0.20
MACD 0.00 0.35
Stochastic Oscillator 0.00 65.02

Price Performance

Historical Comparison
TCRT
GOVX

About TCRT Alaunos Therapeutics Inc.

Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Share on Social Networks: